3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
20
Gemcitabine
10
Nivolumab
8
Irinotecan
8
atezolizumab
7
durvalumab
6
Docetaxel
6
sargramostim
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
aldesleukin
4
Psychiatric Rehabilitation
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Cisplatin
4
tislelizumab
3
spartalizumab
3
avelumab
3
Topotecan
3
Therapeutics
3
Polymerase Chain Reaction
3
Carboplatin
3
Bevacizumab
3
tremelimumab
2
talazoparib
2
surufatinib
2
regorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
tinostamustine
×
Gastrointestinal
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts